A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

This Phase 2 study tests ABSK021, a new oral targeted therapy, as a first-line treatment for patients with locally advanced or metastatic pancreatic cancer that cannot be surgically removed. Researchers aim to evaluate how well the drug works and whether it is safe. **You may be eligible if...** - You are between 18 and 75 years old with advanced or metastatic pancreatic cancer confirmed by biopsy - You have not received prior systemic treatment for pancreatic cancer - You have measurable disease on scans - Your estimated survival is at least 3 months - You have adequate blood counts and organ function **You may NOT be eligible if...** - You have a BRCA1 or BRCA2 gene mutation - You have had another cancer in the past 5 years - You have a history of interstitial lung disease or immune deficiency - You have active brain metastases (cancer spread to the brain) - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.